End-Stage Kidney Disease Treatment Market Size, Industry Trends, Share and Forecast 2021-2027

The global end-stage kidney disease treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027. End-stage kidney disease is also called an end-stage renal disease or kidney failure. It occurs when chronic kidney disease or the gradual loss of kidney function reaches an advanced state and kidneys that can no longer work to meet the body's needs. The major factor driving the market growth is the rising prevalence of kidney disease across the globe.

According to the National Institute of Diabetes and Digestive and Kidney Disease, kidney disease affects more than 1 in 7 adults in the US with an estimated 37 million Americans in 2021. Additionally, it is more common in women with 14% than men 12%. Furthermore, about 14% of Hispanic adults have kidney disease in the US. Moreover, KD is most common in people aged 65 or older (38%) which is followed by people aged 45 to 64 (12%) and people aged 18 to 44 (6%). Apart from this, approximately 786,000 people are living with end-stage kidney disease (ESKD) with 71% on dialysis and 29% with a kidney transplant In the US. Hence, the rising prevalence of kidney disease is driving the demand for end-stage kidney disease treatment which in turn is driving the growth of the market.

To Request a Sample of our Report on End-Stage Kidney Disease Treatment Market: https://www.omrglobal.com/request-sample/end-stage-kidney-disease-treatment-market

Some major players operating in the market include Novartis International AG, Merck & Co., Inc., and Bayer AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, the US Food and Drug Administration (FDA) approved Bayer KERENDIA (finerenone) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, CVD death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Treatment

· By Drugs

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Novartis International AG, Merck & Co., Inc., and Bayer AG, among others

(Get 15% Discount on Buying this Report)

A full Report of End-Stage Kidney Disease Treatment Market is Available @ https://www.omrglobal.com/industry-reports/end-stage-kidney-disease-treatment-market

Global End Stage Kidney Disease Treatment Market Report Segment

By Treatment

· Kidney Transplantation

· Dialysis

By Drugs

· Sanguinate

· MK-3866

· Pacritinib

· Tesidolumab

· Others

Global End Stage Kidney Disease Treatment Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.